Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib)...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER )
Also on site :
- Ukraine doing West’s ‘dirty work’ in Africa – Sudanese official
- 'He knows where to find me,' Newsom responds to Trump administration arrest threat
- Two people killed by falling trees and thousands without power after storms sweep southern states